Nishioka N, Naito T, Notsu A, et al. - In patients suffering from advanced non‐small cell lung cancer (NSCLC) managed with PD‐1/PD‐L1 inhibitor monotherapy between March 2016 and February 2018, researchers undertook a retrospective review to determine how muscular quality could impact the therapeutic effects of immune checkpoint inhibitors. There were 156 patients included, and of those, 80 (51.3%) showed low muscle quality and 47 (30.1%) exhibited low muscle quantity. Higher overall response rate (35.0 vs 15.8 %) and longer progression‐free survival (median, 4.5 vs 2.0 months) were noted in patients with high muscle quality vs those with low muscle quality. Between patients with high and those with low muscle quantities, there were no noted differences in ORR or PFS. No disparities in overall survival were seen between patients with high and those with low muscle status, irrespective of muscle quality and quantity. Findings showed that lumbar skeletal muscle quality may have value in predicting the therapeutic impact of anti‐ PD‐1/PD‐L1 inhibitor monotherapy in patients suffering from advanced NSCLC.